BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 12,540 shares of the firm’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $19.50, for a total value of $244,530.00. Following the completion of the sale, the chief executive officer now directly owns 152,057 shares in the company, valued at $2,965,111.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Rice also recently made the following trade(s):

  • On Monday, July 16th, Michael Rice sold 12,540 shares of BioLife Solutions stock. The shares were sold at an average price of $19.90, for a total value of $249,546.00.
  • On Monday, June 18th, Michael Rice sold 12,540 shares of BioLife Solutions stock. The shares were sold at an average price of $12.89, for a total value of $161,640.60.

Shares of NASDAQ BLFS traded up $0.49 during mid-day trading on Friday, hitting $19.78. The company had a trading volume of 3,157 shares, compared to its average volume of 178,450. BioLife Solutions Inc has a 12 month low of $3.68 and a 12 month high of $22.86. The stock has a market cap of $324.63 million, a PE ratio of -92.95 and a beta of 0.64.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.01. BioLife Solutions had a net margin of 1.76% and a return on equity of 2.24%. The business had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.20 million. sell-side analysts predict that BioLife Solutions Inc will post 0.14 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN bought a new stake in shares of BioLife Solutions in the fourth quarter valued at about $111,000. Bank of Montreal Can bought a new stake in shares of BioLife Solutions in the second quarter valued at about $114,000. Kovack Advisors Inc. bought a new stake in shares of BioLife Solutions in the second quarter valued at about $126,000. OppenheimerFunds Inc. bought a new stake in shares of BioLife Solutions in the second quarter valued at about $130,000. Finally, Jane Street Group LLC bought a new stake in shares of BioLife Solutions in the second quarter valued at about $173,000. Institutional investors and hedge funds own 16.34% of the company’s stock.

BLFS has been the topic of several research analyst reports. B. Riley initiated coverage on BioLife Solutions in a research report on Thursday, June 7th. They issued a “buy” rating and a $14.00 price target on the stock. ValuEngine raised BioLife Solutions from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 4th. Maxim Group increased their target price on shares of BioLife Solutions from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 11th. Finally, Northland Securities reiterated a “buy” rating and issued a $18.00 target price on shares of BioLife Solutions in a research note on Friday, August 10th.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Featured Story: Should I follow buy, hold and sell recommendations?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.